This is a transformative clinical data readout for a pre-revenue biotech. The 100% ORR and 18.2-month OS substantially exceed historical benchmarks, and the FDA discussion for a larger U.S. study adds a clear near-term catalyst. Expect significant upside momentum; monitor for any equity offering to fund the larger trial.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $13.32entry
- T+1 · 4mo ago −2.33%α −2.21% · $13.01
- T+5 · 4mo ago −8.33%α −7.11% · $12.21
- T+20 · 3mo ago +7.06%α +4.50% · $14.26
- T+60 · 5w ago +3.15%α −0.82% · $13.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau reported positive clinical data from a study of Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The combination produced a 100% objective response rate (ORR) and a median overall survival of 18.2 months among evaluable patients, significantly exceeding historical benchmarks for pembrolizumab monotherapy (19% ORR, 12.3 months OS). The trial met its pre-specified success criterion, and the company is discussing a larger U.S. study with the FDA, representing a major pipeline catalyst for this pre-revenue oncology company.
Key Facts
- Alpha DaRT plus pembrolizumab produced a 100% objective response rate (ORR) in 9 evaluable patients with HNSCC, vs. ~19% historical benchmark for pembrolizumab monotherapy.
- Median overall survival was 18.2 months, vs. 12.3 months for pembrolizumab monotherapy in KEYNOTE-048.
- Median progression-free survival was 5.4 months, vs. 3.2 months for pembrolizumab monotherapy.
- No Alpha DaRT-related serious adverse events were observed; only two Grade 1 adverse events were reported.
- The trial met its pre-specified success criterion (more than six patients responding), and enrollment was concluded.
- Company is in ongoing discussions with the FDA regarding a larger U.S. study of the combination.
Financial Impact
No financial figures reported; company is pre-revenue. The positive data is a significant pipeline catalyst that could accelerate regulatory pathway and partnership potential.
Risk Factors
- Small sample size (9 evaluable patients), results may not replicate in larger, controlled studies.
- Single-center, open-label, single-arm design limits comparability to standard of care.
- Company is pre-revenue and will require additional capital to fund larger trials and potential commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079822 |
| Document: ea0298609-6k_alpha.htm | 0001213900-26-079822 |
| Document: 0001213900-26-079822-index-headers.html | 0001213900-26-079822 |
| Document: 0001213900-26-079822-index.html | 0001213900-26-079822 |
| Document: 0001213900-26-079822.txt | 0001213900-26-079822 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers